Stock Taper
AMGN
AMGEN INC.
NASDAQ
$381.50
▲ UP 1.10% (4.15)

KEY STATISTICS

Market Cap$203.66 B
52w High$447.03
52w Low$269.77
Dividend Yield2.58%
FrequencyQuarterly
P/E17.05
Volume2.62M
Shares Out.539.71M

COMPANY

LEADERSHIP

Robert A. Bradway
CHIEF EXECUTIVE
Robert A. Bradway

COMPENSATION 2026

Salary$1,925,409
Stock Awards$12,599,589
Incentive Plan Pay$3,907,000
All Other Comp.$861,126
Total$24,693,120

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 17, 1983
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
31,500

PRICE TARGET

Target High$460.00
Target Low$230.00
Target Median$394.50
Target Consensus$393.17

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$10.05B
NOV
3
TUE

SPLIT RECORD

DATETYPERATIO
1999-11-22Forward2:1
1999-03-01Forward2:1
1995-08-16Forward2:1
1991-09-11Forward3:1
1990-08-13Forward2:1

PRICE

$381.50 ▲ UP 1.10% (+$4.15)
OVERLAYS
$378$380$3829:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM381.50

About Amgen Inc.

https://www.amgen.com ↗

Amgen Inc. is a global biotech company that develops and markets human therapeutics across areas like oncology, inflammation, and cardiovascular disease, partnering with various firms to innovate and distribute a broad portfolio of medicines.

INDUSTRY

Drug Manufacturers - General

A PRODUCT AMGEN INC. IS KNOWN FOR

Uplizna® (inebilizumab)
Uplizna® (inebilizumab)

Uplizna, a monoclonal antibody approved in 2025-2026 for generalized myasthenia gravis, marks a significant advancement in autoimmune treatment and reflects Amgen's focus on inflammation and rare diseases.

RATINGS SNAPSHOT

Overall rating: B+

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity5
Return On Assets5
Debt To Equity1
Price To Earnings2
Price To Book1
Overall Score3

TRADES BY CONGRESS

SENATE TRADES
Sheldon Whitehouse
Sheldon Whitehouse
Sale
2026-08-12
HOUSE TRADES
David J. Taylor
David J. Taylor
Purchase
2026-06-05
Ro Khanna
Ro Khanna
Purchase
2026-06-02
Maria Elvira Salazar
Maria Elvira Salazar
Sale
2026-04-17

INSIDER TRADES

OFFICER: EVP & CFO
Dittrich Thomas J.W.
· —
2026-09-01
OFFICER: EVP & CFO
Dittrich Thomas J.W.
· 17.2K shares
2027-08-07
OFFICER: SVP, BUSINESS DEVELOPMENT
Khosla Rachna
Sale · 2.0K shares
2026-08-11
OFFICER: SVP, BUSINESS DEVELOPMENT
Khosla Rachna
Sale · 1.3K shares
2026-08-13

MOST RECENT ANALYST GRADES

GRADE SUMMARY
HOLD 4
NEUTRAL 4
BUY 4
EQUAL WEIGHT 3
OUTPERFORM 3
MARKET PERFORM 2
UNDERPERFORM 2
OVERWEIGHT 1
SECTOR OUTPERFORM 1
24 GRADES IN THE LAST 12 MONTHS

SECTORS PEERS

PEERPRICE
MRK$145.31COMPARE
NVS$139.56COMPARE
NVO$43.47COMPARE
GILD$145.15COMPARE
PFE$27.74COMPARE
DHR$202.74COMPARE
BMY$64.03COMPARE
SNY$43.43COMPARE